Simvastatin and Rifaximin for Patients With Decompensated Cirrhosis

To the Editor We read with great interest the recent trial suggesting that the addition of simvastatin and rifaximin to standard therapy did not improve the prognosis of patients with decompensated cirrhosis. However, we believe that a more detailed presentation of the study’s data would be beneficial to help refine the decision-making process about treatment strategies for decompensated cirrhosis.